Skip to main content
. 2023 Jan 12;11(3):306–319. doi: 10.1158/2326-6066.CIR-22-0454

Figure 5.

Figure 5. The relationship between CD161+ CTLs and treatment response. A and B, Waterfall plot showing response of patients from the test cohort (n = 27–29) to induction chemotherapy according to the proportion of CD161+ CTLs in the tumor microenvironment. X axis represents each patient annotated with their HPV status; Y axis represents the percentage of maximum tumor reduction. Asterisks represent new lesions after the treatment. Dashed lines mark tumor progression of 20% or reduction of 30%, 100%, which defined PD or PR and CR, respectively. C and D, Waterfall plot showing the response of patients (n = 26–28) to the radiotherapy following the induction chemotherapy according to the proportion of CD161+ CTLs in the tumor microenvironment. E, Patients (n = 53) from the validation cohort were divided by HPV status and ordered by the density of CD8+ T cells. Top: number of CD8+ cells and CD161+ cells in the tumor microenvironment; middle: composition and spatial distribution within CD8+ T cells; bottom: HPV status, location, stage, and response to treatment of each patient N, HPV-negative; P, HPV-positive; T, tonsil; BT, base of tongue; SP, soft palate; PW, posterior wall; CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.

The relationship between CD161+ CTLs and treatment response. A and B, Waterfall plot showing response of patients from the test cohort (n = 27–29) to induction chemotherapy according to the proportion of CD161+ CTLs in the tumor microenvironment. X axis represents each patient annotated with their HPV status; Y axis represents the percentage of maximum tumor reduction. Asterisks represent new lesions after the treatment. Dashed lines mark tumor progression of 20% or reduction of 30%, 100%, which defined PD or PR and CR, respectively. C and D, Waterfall plot showing the response of patients (n = 26–28) to the radiotherapy following the induction chemotherapy according to the proportion of CD161+ CTLs in the tumor microenvironment. E, Patients (n = 53) from the validation cohort were divided by HPV status and ordered by the density of CD8+ T cells. Top: number of CD8+ cells and CD161+ cells in the tumor microenvironment; middle: composition and spatial distribution within CD8+ T cells; bottom: HPV status, location, stage, and response to treatment of each patient. N, HPV-negative; P, HPV-positive; T, tonsil; BT, base of tongue; SP, soft palate; PW, posterior wall; CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.